Supernus Pharmaceuticals | SUPN - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Abbott USD 5.86B 675M 2026-03
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Aurora Cannabis CAD 46.62M 14.33M 2025-12
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Canopy Growth CAD 21.47M 434K 2025-12
Cara Therapeutics USD 2.57M 1.11M 2025-03
Corcept Therapeutics USD 162.02M 37.56M 2026-03
Eisai JPY 168.85B 17.02B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Novo Nordisk DKK 64.01B 1.19B 2025-06
Pacira USD 126.64M 15.61M 2026-03
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 12.28B 8.74B 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Xeris Pharmaceuticals USD 72.15M 8.77M 2025-12